Literature DB >> 8994656

Immunobead RT-PCR: a sensitive method for detection of circulating tumor cells.

M C Eaton1, J E Hardingham, D Kotasek, A Dobrovic.   

Abstract

Detection of circulating tumor cells and micrometastases in patients with cancer should prove useful in determining prognosis and in planning and monitoring systemic therapies. We have developed immunomagnetic isolation of carcinoma cells followed by reverse transcription polymerase chain reaction (immunobead RT-PCR) as a method for identifying very small numbers of breast cancer cells in blood. The expression of cytokeratin 19 (K19) was used as the marker by which the isolated tumor cells were identified. The immunobead RT-PCR technique allowed detection of one tumor cell per 10(6) leukocytes in whole blood. Immunobead RT-PCR is a highly sensitive method of detecting cancer cells in a hematopoietic environment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8994656     DOI: 10.2144/97221st01

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  13 in total

1.  Detection of circulating epithelial cells after surgery for benign breast disease.

Authors:  D Crisan; D S Ruark; D A Decker; A M Drevon; R G Dicarlo
Journal:  Mol Diagn       Date:  2000-03

2.  Differential interaction of magnetic nanoparticles with tumor cells and peripheral blood cells.

Authors:  J H Clement; M Schwalbe; N Buske; K Wagner; M Schnabelrauch; P Görnert; K O Kliche; K Pachmann; W Weitschies; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-24       Impact factor: 4.553

3.  Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells.

Authors:  J M Silva; R Rodriguez; J M Garcia; C Muñoz; J Silva; G Dominguez; M Provencio; P España; F Bonilla
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

4.  Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells.

Authors:  R L Houghton; D C Dillon; D A Molesh; B K Zehentner; J Xu; J Jiang; C Schmidt; A Frudakis; E Repasky; A Maltez Filho; M Nolasco; R Badaro; X Zhang; P C Roche; D H Persing; S G Reed
Journal:  Mol Diagn       Date:  2001-06

5.  Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles.

Authors:  Siri Tveito; Kristin Andersen; Rolf Kåresen; Øystein Fodstad
Journal:  Breast Cancer Res       Date:  2011-08-04       Impact factor: 6.466

6.  Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells.

Authors:  Michael Raynor; Sally-Anne Stephenson; David C A Walsh; Kenneth B Pittman; Alexander Dobrovic
Journal:  BMC Cancer       Date:  2002-05-24       Impact factor: 4.430

7.  DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients.

Authors:  Tina Bianco-Miotto; Damian J Hussey; Tanya K Day; Denise S O'Keefe; Alexander Dobrovic
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

8.  Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR.

Authors:  Michael P Raynor; Sally-Anne Stephenson; Kenneth B Pittman; David C A Walsh; Michael A Henderson; Alexander Dobrovic
Journal:  J Hematol Oncol       Date:  2009-06-05       Impact factor: 17.388

9.  Long term survival following the detection of circulating tumour cells in head and neck squamous cell carcinoma.

Authors:  Stuart C Winter; Sally-Anne Stephenson; Selva K Subramaniam; Vinidh Paleri; Kien Ha; Conor Marnane; Suren Krishnan; Guy Rees
Journal:  BMC Cancer       Date:  2009-12-06       Impact factor: 4.430

10.  Gene expression of circulating tumour cells in breast cancer patients.

Authors:  E Bölke; K Orth; P A Gerber; G Lammering; R Mota; M Peiper; C Matuschek; W Budach; E Rusnak; S Shaikh; B Dogan; H B Prisack; Hans Bojar
Journal:  Eur J Med Res       Date:  2009-09-28       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.